Health
Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19) – News-Medical.Net
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to…
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.
The team’s SARS-BLOCK™ peptides competitively inhibit the receptor-binding domain (RBD) on the SARS-CoV-2 spike protein – the surface structure that binds the host cell angiotensin-converting enzyme 2 (ACE2) receptor, to…
-
Noosa News15 hours agoFull house as Minister shares vision for Sunshine Coast transport
-
Business12 hours agoWhy I’d buy these top ASX 200 shares next
-
Business10 hours ago10 reasons to buy and hold this tech stock forever
-
General12 hours agoDash cam video shows spectacular Finke Desert Race crash